Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
Seulki Kim(Seoul National University), Dae Seog Heo(Seoul National University Hospital)
Cited by 66
Related Papers
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
|Oncotarget|2017|87
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients
|Scientific Reports|2019|46
Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma
|World Journal of Gastroenterology|2016|31
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
|Cancer Research and Treatment|2018|28
Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC
|Journal of Thoracic Oncology|2021|27